William du Comb, DO
Urology · Burlington, MANPI 1528590486
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Boston Scientific at 55.4% of the total. Reporting peaked in 2023 at $5,081 and has fallen 99.0% since, to $51 in 2025.
Across 79 payments — averaging $112.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Coloplast$4K
- Teleflex LLC$134
- AbbVie$92
- Merck$36
- Hollister Incorporated$16
What the payments were for
- Consulting fees$4005%
- Travel & lodging$4,60552%
- Food & beverage$3,60341%
- Education$2803%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 46 | $4,920 |
| Coloplast | 28 | $3,689 |
| Teleflex LLC | 1 | $134 |
| AbbVie | 1 | $92 |
| Merck | 2 | $36 |
| Hollister Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$3,091
- AMS 700 CXR RTE KIT$1,362
- GENERAL - THERAPIES$1,339
- TACTRA$400
- UroLift System$134
- AMS 700$108
- AMS$103
How this compares
$8,887 in reported general payments places this provider in the 80th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 50 | $28,171 |
| GemtesaVibegron | 23 | $13,729 |
| Mirabegron ErMirabegron | 16 | $5,835 |
| Testosterone | 12 | $3,605 |
| Trospium Chloride | 46 | $2,796 |
| Tamsulosin Hcl | 212 | $2,529 |
| Methenamine Hippurate | 35 | $2,145 |
| Estradiol | 21 | $1,534 |
| Finasteride | 76 | $616 |
| Cabergoline | 11 | $571 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $491 |
| Cefdinir | 32 | $482 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 21 | $456 |
| Testosterone Cypionate | 23 | $395 |
| Dutasteride | 15 | $258 |
Paid to pharmacies, not to this prescriber.
Other urology in Burlington
- Michael CallegariBurlington$53K
- Peris CastanedaBurlington$51K
- Arthur MourtzinosBurlington$43K
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
- Louis LiouCambridge$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.